A NEW class of drug presented at
the American College of Cardiology
2014 Scientific Sessions generated
such enthusiasm that not everyone
could fit in the lecture room.
PCSK9 inhibitors are a new
class of therapy for reduction of
low density lipoproteins (LDL)
cholesterol.
Three new chemical entities
were presented: evolocumab
from Amgen, alirocumab from
Regeneron Pharmaceuticals and
bococizumab from pharmaceutical
giant Pfizer.The above article was sent to subscribers in Pharmacy Daily's issue from 02 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Apr 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.